Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis.
Central Composite Design
PTH (1-34)
Targeting
anabolic peptide
bone
osteoporosis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
11 Feb 2023
11 Feb 2023
Historique:
received:
31
12
2022
revised:
03
02
2023
accepted:
09
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Bone-specific functionalization strategies on liposomes are promising approaches to delivering the drug in osteoporotic conditions. This approach delivers the drug to the bone surface specifically, reduces the dose and off-target effects of the drug, and thereby reduces the toxicity of the drug. The purpose of the current research work was to fabricate the bone-specific peptide conjugated pegylated nanoliposomes to deliver anabolic drug and its physicochemical evaluations. For this, a bone-specific peptide (SDSSD) was synthesized, and the synthesized peptide was conjugated with a linker (DSPE-PEG2000-COOH) to obtain a bone-specific conjugate (SDSSD-DSPE). Purified SDSSD-DSPE was characterized by HPLC, Maldi-TOF, NMR, and Scanning Electron Microscope/Energy Dispersive Spectroscopy (SEM/EDS). Further, peptide-conjugated and anabolic drug-encapsulated liposomes (SDSSD-LPs) were developed using the ethanol injection method and optimized by Central Composite Design (CCD) using a statistical approach. Optimized SDSSD-LPs were evaluated for their physicochemical properties, including surface morphology, particle size, zeta potential, in vitro drug release, and bone mineral binding potential. The obtained results from these studies demonstrated that SDSSD-DSPE conjugate and SDSSD-LPs were optimized successfully. The particle size, % EE, and zeta potential of SDSSD-LPs were observed to be 183.07 ± 0.85 nm, 66.72 ± 4.22%, and -25.03 ± 0.21 mV, respectively. SDSSD-LPs demonstrated a sustained drug release profile. Further, the in vitro bone mineral binding assay demonstrated that SDSSD-LPs deliver the drug to the bone surface specifically. These results suggested that SDSSD-LPs could be a potential targeting approach to deliver the anabolic drug in osteoporotic conditions.
Identifiants
pubmed: 36839930
pii: pharmaceutics15020608
doi: 10.3390/pharmaceutics15020608
pmc: PMC9965365
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharm Nanotechnol. 2022 Sep 02;:
pubmed: 36056842
Curr Protein Pept Sci. 2022;23(7):495-503
pubmed: 35996259
Lancet Diabetes Endocrinol. 2017 Nov;5(11):898-907
pubmed: 28689769
Nat Med. 2012 Jan 29;18(2):307-14
pubmed: 22286306
Int J Mol Sci. 2021 May 03;22(9):
pubmed: 34063731
Acta Biomater. 2009 May;5(4):1241-52
pubmed: 19083277
J Pharm Pharmacol. 2017 Aug;69(8):991-1001
pubmed: 28444771
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):173-178
pubmed: 29263728
Pharm Dev Technol. 2016 Sep;21(6):680-7
pubmed: 25975585
Exp Ther Med. 2018 Jan;15(1):19-30
pubmed: 29387179
Langmuir. 2005 May 24;21(11):5185-91
pubmed: 15896069
J Orthop Translat. 2022 Oct 17;38:23-31
pubmed: 36313979
Int J Nanomedicine. 2022 Jun 07;17:2593-2608
pubmed: 35698561
Sci Rep. 2021 Dec 14;11(1):23956
pubmed: 34907232
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Lancet. 2002 Jun 1;359(9321):1929-36
pubmed: 12057569
Molecules. 2021 Sep 07;26(18):
pubmed: 34576904
Curr Osteoporos Rep. 2013 Dec;11(4):400-6
pubmed: 24078470
ACS Appl Bio Mater. 2020 Jun 15;3(6):3569-3581
pubmed: 35025227
Biomater Sci. 2022 Mar 29;10(7):1765-1775
pubmed: 35212326
J Liposome Res. 2010 Sep;20(3):228-43
pubmed: 19899957
Drug Deliv. 2007 Aug;14(6):327-35
pubmed: 17701522
ACS Nano. 2016 Jun 28;10(6):5759-68
pubmed: 27176123
Calcif Tissue Int. 2010 Jan;86(1):58-66
pubmed: 19949943
Sci Rep. 2021 Mar 3;11(1):5107
pubmed: 33658580
Int J Pharm. 2022 Aug 25;624:122022
pubmed: 35843364
Nat Rev Endocrinol. 2011 Sep 06;8(2):81-91
pubmed: 21894214
J R Soc Interface. 2016 Oct;13(123):
pubmed: 27707904
Bioact Mater. 2021 Sep 17;10:207-221
pubmed: 34901540
Int J Nanomedicine. 2019 Aug 02;14:6151-6163
pubmed: 31447557
Pharmaceutics. 2022 Nov 09;14(11):
pubmed: 36365235
J AOAC Int. 2022 Dec 22;106(1):40-48
pubmed: 35972348
Nat Rev Endocrinol. 2021 Jan;17(1):31-46
pubmed: 33149262
Langmuir. 2007 Nov 20;23(24):12233-42
pubmed: 17963411